(Boston)-Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found that sexual behavior counseling during drug addiction treatment should be considered an important component among Russian substance-dependent individuals, in order to decrease risky sexual behavior in the HIV at-risk population. This study appears in the journal Addiction.
Russia has one of the fastest-growing acquired immune deficiency syndrome (AIDS) epidemics in the world. Mainly prevalent among injection drug users, HIV now is expanding into the general population via sexual transmission. According to research, alcohol use is highly pervasive in Russia, and has been associated with sexual HIV risk-taking behavior. According to lead author Jeffrey Samet, MD, chief of the Section of General Internal Medicine at BMC and BUSM, "a behavioral intervention to reduce unsafe sex is an essential component to HIV prevention, and is critical in the absence of a cure or vaccine."
Researchers compared the current method used to decrease unsafe sexual behavior with the Russian Partnership to Reduce the Epidemic Via Engagement in Narcology Treatment (PREVENT) intervention program. Participants were HIV-positive and negative, and were assigned to either the PREVENT program or the standard addiction treatment.
PREVENT sessions occurred at the hospital and involved obtaining HIV test results, discussion of personal risk and creation of a behavioral change plan. Interventionists provided test results and explained the risk reduction plan to promote safe sex that included using condoms, building sexual-negotiation skills, developing positive attitudes regarding safe sex and emphasizing alcohol and drugs role in impairing judgment. After patients were discharged from the hospital, telephone updates took place for three months. Interventionists checked in and updated participants' personal long-term risk reduction goals and plans.
Participants assigned to the standard addiction treatment program received the usual addiction treatment at the hospital, including HIV testing, but no sexual behavior counseling. Those known to be HIV-infected or who tested positive received a 20-minute HIV post-test counseling session with the study interventionists. This session included creating risk reduction goals and a referral to an HIV care program. Subjects were contacted for study check ups, but not counseled. Both participants of the standard addiction treatment and PREVENT program received condoms upon leaving the hospital.
The researchers found that when comparing the two forms of intervention, participants of the PREVENT program had a higher percentage of safe sex than did the standard addiction participants at the six month follow-up visits. "Both control and intervention groups had improvements in the percentage of safe sex occurrences, restraining from unprotected sex and increasing condom use between baseline and the three month follow-up. While the intervention group maintained or improved their safe sex behaviors at the six month follow-up, the standard addiction treatment group worsened," said Samet.
The Russian PREVENT trial demonstrates that an HIV intervention program targeting the sexual behaviors of alcohol and drug users is feasible in inpatient substance abuse treatment settings, and is effective in increasing safe sex.
Source: Boston University
Related stories:
Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV
While the U.S. AIDS epidemic simmers largely unnoticed by most Americans, a failure to widely implement routine HIV testing continues to fuel its spread, HIV researchers and experts said today. Almost 60,000 Americans were infected with HIV last year, and, nationwide, 50-to-70 percent of new sexually transmitted infections are spread by people who do not know they are infected.
Guidelines issued two years ago by the U.S. Centers for Disease Control and Prevention (CDC) recommend that all Americans ages 13-64 be routinely tested in all healthcare settings. Now, data show that although such testing could save years of healthy life and limit the spread of HIV, they are largely not being implemented.
Cases of extensively drug-resistant TB declining each year in the US, but new cases still
A new report suggests that the number of cases of extensively drug-resistant tuberculosis (XDR-TB) in the U.S. has declined in the past fifteen years, but new cases continue to be reported, according to the study published in the November 12 issue of
JAMA. The researchers note the decrease in the number of XDR-TB cases coincides with improved TB and HIV/AIDS control.
Researcher invents molecule that stops SARS
A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease.
New HIV-reduction initiative takes to the fields
Education has found its way onto the soccer fields of North Carolina – in the form of a social experiment that may have all the right ingredients to change the direction of Latino health in the United States.
Researchers hone in on new strategy to treat common infection
Researchers at Georgetown University Medical Center (GUMC) have successfully tested a genetic strategy designed to improve treatment of human infections caused by the yeast
Candida albicans, ranging from diaper rash, vaginitis, oral infections (or thrush which is common in HIV/AIDS patients), as well as invasive, blood-borne and life-threatening diseases.
Study examines repeated exposure to HIV in treatment-suppressed HIV patients
A new study looking at unprotected intercourse within gay couples when each partner has established HIV-infection found a correlation between anti-HIV immune response and sexual activity.
Researchers estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa
Boston, MA – More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 because a feasible and timely antiretroviral (ARV) treatment program was not implemented, assert researchers from the Harvard School of Public Health (HSPH) in a study published online by the
Journal of Acquired Immune Deficiency Syndromes (JAIDS) (
http://www.jaids.com/). In addition, an estimated 35,000 babies were born with HIV during that same period in the country because a feasible mother-to-child transmission prophylaxis program using nevirapine (an anti-AIDS drug) was not implemented, the authors write.
Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. Nevirapine is the most frequently prescribed drug for patients undergoing highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS in sub-Saharan Africa, where the study was conducted. The study is published in the October 18, 2008 issue of the journal
AIDS.